Skip to main content
Syncona Limited logo

Syncona Limited — Investor Relations & Filings

Ticker · SYNC ISIN · GG00B8P59C08 LEI · 213800X8MBI5VQITLW60 IL Financial and insurance activities
Open in API
Filings indexed 1,030 across all filing types
Latest filing 2024-02-08 Regulatory Filings
Country GG Guernsey
Listing IL SYNC

About Syncona Limited

https://www.synconaltd.com/

Syncona Limited is a life science investment company focused on founding, building, and funding a portfolio of healthcare businesses. The company's strategy is to identify and advance exceptional science to create globally leading companies capable of delivering transformational treatments to patients, particularly in areas with high unmet medical needs. Its portfolio is concentrated in innovative therapeutic areas, including gene therapy, cell therapy, and biologics. Syncona actively manages its companies to reach key value inflection points, aiming to generate significant long-term capital appreciation for shareholders through strategic events such as mergers, acquisitions, and other liquidity events.

Recent filings

Filing Released Lang Actions
Beacon presents 12-month clinical data
Regulatory Filings Classification · 1% confidence The document is an announcement released via RNS (RNS Number : 4067C) on February 8, 2024. It details that Syncona's portfolio company, Beacon Therapeutics, presented 12-month clinical data from its Phase II SKYLINE trial at a medical meeting (47th Annual Macula Society Meeting). The text summarizes key efficacy and safety results and mentions where the full presentation can be accessed. Since this is a formal announcement disseminated through a regulatory news service (RNS) reporting on clinical trial data presentation, it fits best under the general 'Regulatory Filings' category (RNS) as it is not a full Earnings Release (ER), Interim Report (IR), or a specific management/governance document. It is a general corporate update distributed via the official channel.
2024-02-08 English
Autolus announces Strategic Collaboration
Regulatory Filings Classification · 1% confidence The document is an announcement originating from Syncona Limited, noting that its portfolio company, Autolus Therapeutics plc, has entered into a strategic collaboration and financing agreement with BioNTech SE. The text details specific financial transactions ($200M ADS purchase, $50M cash payment), licensing terms, royalty structures, and options related to drug development (CAR-T programs). This type of announcement, detailing significant corporate financing, strategic partnerships, and material changes in business operations involving equity investment and licensing, strongly aligns with the definition of a Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple dividend notice (DIV). Since it involves a significant investment ($200M purchase of ADSs) and strategic partnership terms, CAP is the most appropriate classification over a general Regulatory Filing (RNS). The document length is substantial (24,961 chars), indicating it is the primary announcement, not just a brief notice of publication (RPA).
2024-02-08 English
Third Quarter Update
Interim / Quarterly Report Classification · 1% confidence The document is a 'Third Quarter Update' from Syncona Limited, detailing financial performance, net asset value (NAV) movements, portfolio milestones, and management changes for the period ending 31 December 2023. It contains substantive financial data, including a detailed table of valuation movements and portfolio company performance. As it provides comprehensive financial results for a period shorter than a full fiscal year, it qualifies as an Interim/Quarterly Report (IR). Q3 2023
2024-02-08 English
Transaction in Own Shares
Transaction in Own Shares Classification · 1% confidence The document explicitly announces a 'Transaction in Own Shares' detailing the purchase of 120,000 Ordinary Shares as part of a 'share buyback programme'. This directly corresponds to the definition of a company buying back or selling its own shares. The filing uses the RNS (Regulatory News Service) format, but the specific content maps precisely to the 'Transaction in Own Shares' category (POS).
2024-02-08 English
Transaction in Own Shares
Transaction in Own Shares Classification · 1% confidence The document is an official notification released via RNS (Regulatory News Service) on February 7, 2024. The title explicitly states 'Transaction in Own Shares' and details the purchase of 200,000 ordinary shares by Syncona Limited as part of its share buyback programme. This directly corresponds to the definition of a company reporting the repurchase or sale of its own shares. Therefore, the appropriate filing type is 'Transaction in Own Shares' (POS). The document length is short (3242 chars) and contains the full details, so it is not an RPA.
2024-02-07 English
Transaction in Own Shares
Transaction in Own Shares Classification · 1% confidence The document explicitly states 'Transaction in Own Shares' and details the purchase of ordinary shares by the company as part of a 'share buyback programme'. This directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS). Although it is distributed via RNS, the specific nature of the transaction (share repurchase) makes POS the most accurate classification over the general RNS fallback.
2024-02-06 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.